Tanzania - engelska - Tanzania Medicinces & Medical Devices Authority

intas pharmaceuticals limited, india - mycophenolic acid - oral tablet - 360

Turkiet - turkiska - TİTCK (Türkİye İlaç Ve Tibbİ Cİhaz Kurumu)

abdİ İbrahİm İlaÇ san. ve tİc. a.Ş. - combinations of levothyroxine and liothyronine -

Grekland - grekiska - Εθνικός Οργανισμός Φαρμάκων

sandoz pharmaceuticals d.d. (abbr. sandoz d.d.), slovenia verovskova 57, si-1000 ljubljana +386 1 580 2111 - sitagliptin hydrochloride monohydrate; metformin hydrochloride - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (50+850)mg/tab - sitagliptin hydrochloride monohydrate 56,7mg; metformin hydrochloride 850mg - combinations of oral blood glucose lowering drugs

Grekland - grekiska - Εθνικός Οργανισμός Φαρμάκων

sandoz pharmaceuticals d.d. (abbr. sandoz d.d.), slovenia verovskova 57, si-1000 ljubljana +386 1 580 2111 - sitagliptin hydrochloride monohydrate; metformin hydrochloride - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (50+1000)mg/tab - sitagliptin hydrochloride monohydrate 56,7mg; metformin hydrochloride 1.000mg - combinations of oral blood glucose lowering drugs

Malaysia - engelska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

accord healthcare sdn.bhd. - mycophenolic acid (as sodium salt) -

Malaysia - engelska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

accord healthcare sdn.bhd. - mycophenolic acid (as sodium salt) -

Nederländerna - nederländska - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. - mycofenolaat natrium samenstelling overeenkomend met ; mycofenolzuur - maagsapresistente tablet - ammonia (e 527) ; cellulose, microkristallijn (e 460) ; copolymeer van ethylacrylaat-methacrylzuur (1:1) ; croscarmellose natrium (e 468) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; natriumwaterstofcarbonaat (e 500 (ii)) ; povidon k 30 (e 1201) ; propyleenglycol (e 1520) ; schellak glaze, gedeeltelijk veresterd ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505) ; zwarte inkt - mycophenolic acid

Grekland - grekiska - Εθνικός Οργανισμός Φαρμάκων

serum institute of india ltd, pune, india 212/2 hadapsar, 411028 pune +91-20-26993900 - diphtheria and tetanus toxoids - inj.susp (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - diphtheria and tetanus toxoids 2iu - tetanus toxoid, combinations with diphtheria toxoid

Australien - engelska - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 384.8 mg - tablet, enteric coated - excipient ingredients: crospovidone; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide red; hypromellose phthalate; iron oxide yellow; povidone; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 192.4 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; hypromellose phthalate; maize starch; indigo carmine; povidone; titanium dioxide; magnesium stearate; crospovidone; iron oxide yellow; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.